Transaction #25175 · Form 4 · 0001878313-25-000071
MAIA Biotechnology, Inc. · Purchase · Stock Options
MAIA Biotechnology, Inc. · Transacted December 22, 2025 · Filed December 23, 2025
What does this filing report?
An SEC Form 4 filing for MAIA Biotechnology, Inc. records a purchase involving Stock Options on December 22, 2025. The reported quantity was 40,849. The filing date is December 23, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- MAIA Biotechnology, Inc.
- Company CIK
- 0001878313
- Security type
- Derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 40,849
- Reported price
- 1.36
- Reference value
- 55,554.64
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 40,849
- Ownership description
- Not reported
- SEC acceptance time
- Dec 23, 2025, 8:16 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- CHAOUKI STEVEN M ↗
Director
CIK 0001776865
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 40,849
- Conversion / exercise price
- 1.36
- Exercise date
- June 22, 2026
- Expiration date
- December 22, 2028
Filing footnotes & remarks
- F1
- The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.
- F2
- These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.